Diaceutics
The expert recommendations addressed clinical workflow, guideline creation, and reimbursement barriers to precision oncology.
Very Few Patients Eligible for Tissue-Agnostic TRK Inhibitors Get Them, Real-World Analysis Shows
Premium
Data presented at ASCO found that only a dozen out of 800 patients with NTRK-altered advanced solid tumors got Vitrakvi or Rozlytrek over a two-year period.
The FDA approved 21 precision oncology drugs and several companion tests, but the field continued to be plagued by intractable systemic challenges limiting access.
Diaceutics, PMC Identify Ways Lung Cancer Patients Are Losing Out on Precision Oncology Therapies
Premium
Gaps in the biomarker testing process and knowledge deficiencies are keeping nearly two-thirds of lung cancer patients from receiving precision oncology treatments, research shows.
Precision Oncology in 2021: Growing Complexity, Refining Liquid Biopsy Use, Focus on Access Gaps
Amid new treatment options and a growing list of actionable biomarkers, the field last year also focused on the need to better support oncologists and address access gaps for patients.